eCite Digital Repository

Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents

Citation

Valentine, WJ and Palmer, AJ and Lammert, M and Langer, J and Brandle, M, Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents, Clinical Therapeutics: The International, Peer-Reviewed Journal of Drug Therapy, 33, (11) pp. 1698-1712. ISSN 0149-2918 (2011) [Refereed Article]


Preview
PDF
Restricted - Request a copy
4Mb
  

Copyright Statement

Copyright 2011 Elsevier HS Journals, Inc.

DOI: doi:10.1016/j.clinthera.2011.09.022

Abstract

Background: The global clinical and economic burden of type 2 diabetes is substantial. Recently, clinical trials with glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide and exenatide) have shown a multifactorial clinical profile with the potential to address many of the clinical needs of patients and reduce the burden of disease. Objective: The goal of this study was to evaluate the long-term cost-effectiveness of once-daily liraglutide versus exenatide BID in patients with type 2 diabetes who failed to improve with metformin and/or sulfonylurea, based on the results of a previous clinical trial in 6 European countries (Switzerland, Denmark, Norway, Finland, the Netherlands, and Austria). Methods: A validated computer simulation model of diabetes was used to predict life expectancy, qualityadjusted life years (QALYs), and incidence of diabetesrelated complications in patients receiving liraglutide (1.8 mg once daily) or exenatide (10 g BID). Baseline cohort characteristics and treatment effects were derived from the Liraglutide Effect and Action in Diabetes 6 trial. Country-specific complication costs were taken from published sources. Simulations were run over 40 years from third-party payer perspectives. Future costs and clinical benefits were discounted at country-specific discount rates. Sensitivity analyses were performed. Results: Liraglutide was associated with improvements of 0.12 to 0.17 QALY and a reduced incidence of most diabetes-related complications versus exenatide in all settings. Evaluation of total direct medical costs (treatment plus complication costs) suggest that liraglutide was likely to cost between Euro (€) 1023 and €1866 more than exenatide over patients’ lifetimes, leading to incremental cost-effectiveness ratios per QALY gained versus exenatide of: Switzerland, CHF (Swiss francs) 10,950 (€6902); Denmark, Danish krone [kr] 88,160 (€11,805); Norway, Norwegian krone [kr], 111,916 (€13,546); Finland, €8459; the Netherlands, €8119; and Austria, €8516. Conclusions: Long-term projections indicated that liraglutide was associated with benefits in life expectancy, QALYs, and reduced complication rates versus exenatide. Liraglutide was cost-effective from a health care payer perspective in Switzerland, Denmark, Norway, Finland, the Netherlands, and Austria.

Item Details

Item Type:Refereed Article
Keywords:costs, cost-effectiveness, exenatide, liraglutide, type 2 diabetes
Research Division:Medical and Health Sciences
Research Group:Clinical Sciences
Research Field:Endocrinology
Objective Division:Health
Objective Group:Health and Support Services
Objective Field:Health Policy Economic Outcomes
Author:Palmer, AJ (Professor Andrew Palmer)
ID Code:75180
Year Published:2011
Web of Science® Times Cited:12
Deposited By:Menzies Institute for Medical Research
Deposited On:2012-01-17
Last Modified:2017-11-02
Downloads:0

Repository Staff Only: item control page